Literature DB >> 16378772

Progression of chronic kidney disease: can it be prevented or arrested?

Bertrand L Jaber1, Nicolaos E Madias.   

Abstract

Chronic kidney disease constitutes a highly prevalent health problem worldwide. Left untreated, it progresses inexorably to greater levels of severity at variable rates. The morbid impact of chronic kidney disease is heightened by its role as risk factor for cardiovascular disease. In the past two decades, considerable gains have been realized in retarding progression of chronic kidney disease by emphasizing blood pressure control and blockade of the renin-angiotensin system. Notwithstanding, the therapeutic goal of preventing or arresting chronic kidney disease progression remains unfulfilled. Currently attainable rates of decrease in glomerular filtration rate remain at 2 to 8 mL/min/y depending on the underlying disease. It is now believed that to achieve optimal therapeutic targets (proteinuria of <500 mg/day and decrease in glomerular filtration rate of 1 mL/min/y, the average age-related decline) we must introduce novel strategies and a multifaceted approach to treatment that interrupts multiple mechanisms of progression. To this end, and wherever relevant, new approaches to cause-specific treatment must be applied, such as targeted immunosuppression, intensive glycemic control, gene therapy, and enzyme replacement therapy. Furthermore, in all chronic kidney disease, we must interfere more effectively with the multitude of common mechanisms of progression. Established or putative, such approaches include aggressive blood pressure control; advanced renin-angiotensin system blockade; cytokine modulation and antifibrotic therapy; aldosterone blockade; endothelin blockade, nitric oxide modulation and vasopeptidase inhibition; antioxidant therapy; statin therapy; glycosaminoglycan therapy; anemia therapy; dietary restrictions; lifestyle changes; and pharmacogenomic profiling. Such a concerted, multifaceted approach to management might indeed prevent or arrest progression of chronic kidney disease, or even achieve regression of chronic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16378772     DOI: 10.1016/j.amjmed.2005.02.032

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  14 in total

Review 1.  Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD.

Authors:  Wenshan Lv; Fan Fan; Yangang Wang; Ezekiel Gonzalez-Fernandez; Chen Wang; Lili Yang; George W Booz; Richard J Roman
Journal:  Physiol Genomics       Date:  2017-11-10       Impact factor: 3.107

2.  Effects of Niaoduqing Particles () on Delaying Progression of Renal Dysfunction: A Post-trial, Open-Label, Follow-up Study.

Authors:  Ying Zheng; Nian-Song Wang; Yu-Ning Liu; Li-Qun He; Gui-Hua Jian; Xu-Sheng Liu; Zhao-Hui Ni; Xiao-Hong Cheng; Hong-Li Lin; Wen-Hua Zhou; Ya-Ping Wang; Jing-Ai Fang; Ya-Ni He; Hong-Tao Yang; Li-Juan Zhao; Han-Lu Ding; Li-Hua Wang; Ren-Huan Yu; Wen-Ge Li; Zhi-Ming Ye; Wang Guo; Yong-Li Zhan; Hui-Juan Mao; Zhao Hu; Chen Yao; Guang-Yan Cai; Xiang-Mei Chen
Journal:  Chin J Integr Med       Date:  2018-11-22       Impact factor: 1.978

3.  Lifestyle of hemodialysis patients in comparison with outpatients.

Authors:  Sima Moghadasian; Mohammad Hasan Sahebi Hagh; Leila Aghaallah Hokmabadi
Journal:  J Caring Sci       Date:  2012-05-27

Review 4.  Endothelin and the glomerulus in chronic kidney disease.

Authors:  Matthias Barton; Andrey Sorokin
Journal:  Semin Nephrol       Date:  2015-03       Impact factor: 5.299

5.  Anti-proliferative actions of T-type calcium channel inhibition in Thy1 nephritis.

Authors:  Andrea Cove-Smith; Christopher J Mulgrew; Olena Rudyk; Neelanjana Dutt; Linda M McLatchie; Michael J Shattock; Bruce M Hendry
Journal:  Am J Pathol       Date:  2013-06-05       Impact factor: 4.307

6.  Folic acid-mediated fibrosis is driven by C5a receptor 1-mediated activation of kidney myeloid cells.

Authors:  Ranjit K Sahu; Sandhya Xavier; Daniel Chauss; Luopin Wang; Claude Chew; Ronald Taylor; William B Stallcup; Jennie Z Ma; Majid Kazemian; Behdad Afzali; Jörg Köhl; Didier Portilla
Journal:  Am J Physiol Renal Physiol       Date:  2022-04-04

7.  Endothelin-1, big endothelin-1, and nitric oxide in patients with chronic renal disease and hypertension.

Authors:  Ivanka Mikulić; József Petrik; Kresimir Galesić; Zeljko Romić; Ivana Cepelak; Monika Zeljko-Tomić
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

8.  Complement C1r serine protease contributes to kidney fibrosis.

Authors:  Sandhya Xavier; Ranjit K Sahu; Sai Vineela Bontha; Valeria Mass; Ronald P Taylor; Judit Megyesi; Nicole M Thielens; Didier Portilla
Journal:  Am J Physiol Renal Physiol       Date:  2019-09-11

9.  Feasibility and acceptability of the TALK social worker intervention to improve live kidney transplantation.

Authors:  Nicole DePasquale; Felicia Hill-Briggs; Linda Darrell; LaPricia Lewis Boyér; Patti Ephraim; L Ebony Boulware
Journal:  Health Soc Work       Date:  2012-11

10.  Effects of creatine supplementation on renal function: a randomized, double-blind, placebo-controlled clinical trial.

Authors:  Bruno Gualano; Carlos Ugrinowitsch; Rafael Batista Novaes; Guilherme Gianini Artioli; Maria Heloisa Shimizu; Antonio Carlos Seguro; Roger Charles Harris; Antonio Herbert Lancha
Journal:  Eur J Appl Physiol       Date:  2008-01-11       Impact factor: 3.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.